1. In Vivo

Synthetic Biology And The Computerization Of Drug Development

 
• By Melanie Senior

Synthetic biology offers opportunity across many industries, but the ultimate prize may be health care. The millions of dollars investors have poured into companies developing CAR-T cell therapies and gene editing technologies points to growing confidence in the power of gene manipulation to generate novel, approvable therapeutics, even if for now these are just the early steps toward creating fully synthetic organisms.

IV1609_Cover-image_1200x675

Over the last three decades, digital technologies have transformed lifestyles, livelihoods and businesses, creating new wealth, industrial sectors and opportunities. The impact of synthetic biology – which combines biology with engineering to design and create new biological systems – could be 10 times that of the technology revolution, and happen in half the time. So presages Randal J. Kirk, billionaire chairman and CEO of Intrexon Corp., one of a handful of listed companies seeking to drive – and ride – this next revolution. “This [synthetic biology] is the most important, attractive and productive industrial vector in the history of man.”

Engineering DNA, the codebook for life, isn’t new. Recombinant DNA and the creation of manufactured biologicals were the bedrock of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Innovation

More from In Vivo

Turning Defense Into Attack: Snapshots Of A Changing Medtech Market And How To Respond

 
• By Ashley Yeo

Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.

AI Agents Set To Reshape Biopharma’s Workforce And Operations

 
• By David Wild

While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.

MitoRx’s Muscle-Preserving Obesity Drug Takes Aim At GLP-1 Limitations

 
• By Jo Shorthouse

UK biotech targets the root cause of metabolic disease while preserving muscle mass in a crowded obesity market.